| CLLS Snapshot | |
|---|---|
| Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France. | |
| VALUATION DATA | |
| Market Capitalization | $178,445,000 | Price to Sales | 2.00 |
| Earnings per Share | $-1.4100 |
| PE Ratio | None |
| PRICE DATA | |
| Most Recent Close | $2.5000 |
| 52 Week High | $8.29 |
| 52 Week Low | $2.533 |
| 50-Day Moving Average | $12.8 |
| 200-Day Moving Average | $-3.782 |
| All data are from Alpha Vantage as of today. For more infomation on CLLS see Stock Dividend, Valuation, Price and Financial Data for Investors | |
Custom Search